Medeon's strengths lie in its team, which brings expertise, experience and insight into every step of the medical device lifecycle. We have successful entrepreneurs and investors with exemplary records in identifying key unmet, overlooked and emerging clinical needs and building them into successful projects. Our research and design experts develop devices that have not only passed the most rigorous regulatory standards, but are also readily adopted by healthcare professionals around the globe.
Mr. Rongjin Lin is currently the Chairman of Center Labs Inc. and Bioengine Capital Inc. Mr. Lin …
Dr. Shen is a noted venture investor with over 20 years of experience in a wide spectrum of healt…
Chairman and CEO
For over 30 years Dr. Jang has brought novel devices to patients around the world, both as an investor and an entrepreneur. He spent 13 years as General Partner with The Vertical Group, and led prominent medtech companies including Kyphon (acquired by Medtronic), Integrated Vascular Systems (acquired by Abbott), Ensure Medical (acquired by J&J), and Embol-X (acquired by Edwards Lifesciences). Before that, Dr. Jang was Vice president of R&D at Boston Scientific and Vice president for R&D at Cardiovascular Imaging Systems. Dr. Jang currently sits on the boards of Tricorntech.
In 2012, Dr. Jang founded Medeon to bring revolutionary solutions to the medtech sector. He has also become a key mentor for young medtech talent; for instance, he co-founded the Stanford-Taiwan Biomedical Fellowship Program (STB), which brings the best young leaders from Taiwan's medical field to Stanford for multi-disciplinary trainings including biodesign and entrepreneurship.
Dr. Jang received his B.S. in Materials Science from National Tsing-Hua University and completed his Ph.D. in Materials Science at the University of Utah.
VP of Cardiothoracic Surgery Products
Mr. Palermo leads Medeon's Aquedeon project. He is a veteran of the medical device industry with over 30 years of experience and a proven track record in positioning start-up companies for commercialization and successful acquisition. His skills encompass venture fundraising, business development, strategic planning, product development and executive management of companies spanning several market segments with diverse regulatory requirements.
Mr. Palermo has served as chief operating officer of Dextera Surgical, acting CEO of UlceRx Medical, Inc, and medical device consultant for Adjuvant Medical. He was also President and CEO of ReVascular Therapeutics (Acquired by Boston Scientific, 2011), Vice President of Operations and Engineering for Ensure Medical (Acquired by Cordis, J&J, 2006), and Director of Research and Development at Integrated Vascular Systems (Acquired by Abbott Vascular, 2003).
Mr. Palermo received his B.S. in Technical Management from New Hampshire College.
VP of Interventional Products
Dr. Weng serves as Medeon’s Vice President of Interventional Products. He leads Cross-Seal project, which was successfully licensed to Terumo in March, 2018. Dr. Weng is responsible for R&D and co-development service assigned by client.
Before joining Medeon, Dr. Weng was a senior scientist and principle investigator at the Industrial Technology Research Institute (ITRI), where he led advanced technology and product development projects for commercialization. Dr. Weng brings over 20 years of experience in cardiovascular, orthopedic, and liver disease treatments as well as cell therapy. He is the inventor/author of more than 30 patents and scientific publications including in high impact factor journals.
Dr. Weng received his M.S. in Biochemical Sciences at the National Taiwan University, and completed his Ph.D. in Materials Sciences and Engineering at the National Tsing-Hua University. He was also a visiting scientist at the Massachusetts Institute of Technology (MIT).
Executive Vice President
Ms. Chang brings over twenty years of experience in the medical devices industry. She is well-versed in product development and manufacturing processes, with specialized knowledge in navigating regulatory pathways for major markets. She leads Medeon in strategy planning and execution related to regulatory pathways, quality control, and clinical execution for each project.
Prior to joining Medeon, Ms. Chang served as a Lead Auditor in the medical devices division at TUV Rheinland. She has also held positions in marketing, research and development, quality assurance, and regulatory affairs in several medical devices companies. Ms. Chang received her B.S. in Biomedical Engineering from Chung Yuan Christian University.
Spokesperson and Chief Financial Officer
Dr. Jenny Chen, Spokesperson and Deputy Chief Financial Officer Dr. Chen serves as the spokesperson and deputy chief financial officer of Medeon Biodesign. With nearly 20 years of investment and business development experience, Dr. Chen contributes her expertise in strategic investment and due diligence, business development, and financial planning to the Medeon group. Prior to joining Medeon, Dr. Chen was the investment manager of the Taiwan Global Biofund, a leading global biotech venture capital firm based in Taipei, and participated in the initial founding process of Medeon Biodesign. Dr. Chen also held various leadership roles in business development and project management across the healthcare industry, including BioDiscovery, a bioinformatics product company in California, and Industrial Technology Research Institute (ITRI) of Taiwan.
Dr. Chen holds a Ph.D. degree in Microbiology from UC Davis, and an MBA degree in Finance from Rady School of Management, UC San Diego.
Chairman and CEOFor 30+ years Dr. Jang has brought novel devices to patients around the world, both as an investor and an entrepreneur. He spent 13 years as general partner with The Vertical Group, and led prominent medtech companies including Kyphon (acquired by Medtronic), Integrated Vascular Systems (acquired by Abbott), Ensure Medical (acquired by J&J), and Embol-X (acquired by Edwards Lifesciences). Before that, Dr. Jang was vice-president of R&D at Boston Scientific and vice-president for R&D at Cardiovascular Imaging Systems. Dr. Jang currently sits on the boards of Tricorntech. In 2012, Dr. Jang founded Medeon to bring revolutionary solutions to the minimally invasive medtech sector. He has also become a key mentor for young medtech talent; for instance, he co-founded the Stanford-Taiwan Biomedical Fellowship Program (STB), which brings the best young leaders from Taiwan’s medical field to Stanford for multi-disciplinary trainings including biodesign and entrepreneurship.
Mr. Rongjin Lin is currently the Chairman of Center Labs Inc. and Bioengine Capital Inc. Mr. Lin also holds several chief executive management roles in various biopharmaceutical companies and is highly influential in the Taiwan healthcare industry.
Mr. Lin is a highly-respected business leader in Taiwan and has been referred to as the Taiwanese biopharmaceutical industry “Lee Iacocca” due to his success at improving organizational structure, assisting corporate positioning and deploying managerial strategies. For over 20 years, Mr. Lin has actively led the transformation of Center Labs Inc. from a multiple dosage pharmaceutical factory to Taiwan's largest professional oral solution pharmaceutical company. It has subsequently become a biotech industrial bank, focusing on strategic investments and business integration within the biopharmaceutical industry. In recent years, Mr. Lin continues to invest in startups and emerging companies within the healthcare industry, including new drug development, antibody engineering and protein design, cell line generation, biosimilar drugs development and production, medical devices and agricultural biotech in the Greater China Region, Japan, Korea and other Asian countries. Up to now, he is proactively engaged in investing and creating synergistic biotech businesses, leading Taiwanese healthcare companies towards global markets.
Mr. Lin received B.S. degree in Pharmacy from Taipei Medical University, and was awarded the degree of Honorary Doctor in Medical by Taipei Medical University in 2010.
Board DirectorDr. Hong-Jen Chang is currently Chairman and CEO of YFY Biotech Management Company and leads its highly successful Taiwan Global BioFund (TGB), working closely with early-stage founders in the healthcare space. Before joining YFY Group, Dr. Chang enjoyed a distinguished career of public service in healthcare, including serving as deputy minister of health, president & CEO of the Bureau of National Health Insurance, and director general of the Center of Disease Control. This combination of expertise in health insurance, disease control, biopharmaceutical industry, health information systems and venture investing makes Dr. Chang one of the most unique and well-respected leaders in the healthcare space. Dr. Chang received his Master of Science in Public Health from National Taiwan University, and Master of Health Policy and Management from Harvard School of Public Health.
Board DirectorA self-proclaimed “physician for life”, Dr. Chih-Hsiung Wu has overseen the establishment of entire hospital systems. Currently serving as CEO of Hsing Tian Kong Foundation Medical Mission and as the Superintendent of En Chu Kong Hospital, Dr. Wu is also Chair professor of Taipei Medical University and the Executive Director of Taiwan Hospital Association. He has also held numerous roles in clinical medicine, medical education and hospital management. After graduating from Taipei Medical University and completing his surgical training at the Chang Gung Memorial Hospital, Dr. Wu went on to receive his Ph.D. from Dokkyo Medical University in Japan.
Board DirectorDr. Fang is a well-respected surgeon in Taiwan and an active leader in promoting better training programs for residents. In addition to being a Professor of Surgery at the China Medical University (CMU), Dr. Fang is also Associate Dean of Department of Surgery of the CMU Hospital, and takes an active interest in emerging medical technologies. For instance, he has served as Director of CMU Hospital’s 3D Printing Medical Research Center. Dr. Fang completed his undergraduate studies at the Kaohsiung Medical College’s School of Medicine (1994), and received his Ph.D. from the National Taiwan University School of Medicine (2011, Surgical Science Division).
Independent Board DirectorDr. Chih-Hang Yang has mentored many of Taiwan's promising biotech and medtech founders. He played an instrumental role in the creation of the Stanford-Taiwan Biomedical Fellowship Program (STB), which brings young medical leaders from Taiwan to Stanford University for multi-disciplinary trainings in biodesign and medtech entrepreneurship. Dr. Yang’s career has spanned the academic, entrepreneurial and governmental. He was Chairman of Department of Computer Science at Tamkang University and later the dean of academic affairs and vice president of National Kaohsiung First University of Science and Technology. He also served as director general of the Department of International Programs of the National Science Council (now Ministry of Science and Technology), and was later appointed as the director of Science and Technology Division, TECO in San Francisco (effectively Taiwan’s representative on science and technology in Silicon Valley). Dr. Yang received his B.S. degree in Electronic Engineering from Tatung University, and earned both his Master and Ph.D. degree in Electronics and Computer Science at Southampton University in the UK. He also sits on the board of the Taiwan Cultural and Creativity Development Foundation.
Independent Board DirectorA licensed CPA in the United States, Taiwan and China, Dr. Chia-Ying Ma is currently Dean of Office of Research Development and Professor in the Department of Accounting in Soochow University, Taiwan. He is a sought-after consultant for many government committees including the Public Service Pension Fund, the Directorate-General of Budget for Accounting and Statistics, and the National Palace Museum. He received his B.S. degree in Accounting from National ChengChi University, Master's Degree in Accounting from Utah State University, and a Ph.D. Degree in Business and Economics from Lehigh University.
Independent Board Director
Dr. Shen is a noted venture investor with over 20 years of experience in a wide spectrum of healthcare sectors and has held executive positions in portfolio companies in the United States and Greater China. Dr. Shen is currently General Partner and Head of Life Science Investments of Taiwania Capital, the Taiwan government's national investment firm. Dr. Shen was previously President of Allgenesis Biotherapeutics, President of XinChen Ventures, and Managing Director of Cheng Xin Venture Group. Dr. Shen has been a key leader in nurturing early-stage startups and incubating academic projects into biopharmaceutical and medical device businesses.
He received his B.S. degree in Chemical Engineering from the National Tsing-Hua University, and his Ph.D. in Chemical Engineering from the University of Wisconsin, Madison.